CV
CVSA.US Covista Inc.
- Market cap
- USD 3.93B
- P/E
- 14.9x
- P/B
- 2.76x
- ROE
- 19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is CVSA.US undervalued?
Graham numberCVSA.US trades 35.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Covista Inc. fundamental analysis
No fundamental analysis for Covista Inc. yet.
Covista Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Covista Inc.
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology,…
Full company profileCovista Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Covista Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.21B | 1.24B | 1.01B | 1.05B | 907M | 1.38B | 1.45B | 1.58B | 1.79B | 1.95B | 2.05B |
| Gross Profit | 570M | 611M | 545M | 568M | 460M | 652M | 774M | 886M | 1.02B | 1.12B | 1.16B |
| Operating Income | 135M | 230M | 183M | 166M | 157M | 156M | 226M | 217M | 342M | 383M | 392M |
| EBITDA | 258M | 283M | 223M | 266M | 211M | 264M | 326M | 380M | 427M | 445M | 447M |
| Net Income | 122M | 33.8M | 129M | 202M | 76.9M | -162M | 96.9M | 137M | 233M | 252M | 270M |
| EPS | 1.91 | 0.54 | 2.17 | 3.74 | 1.49 | -3.36 | 2.13 | 3.39 | 6.07 | 7.04 | 7.80 |
| Balance Sheet | |||||||||||
| Total Assets | 2.31B | 2.34B | 2.24B | 2.23B | 3.08B | 3.03B | 2.81B | 2.74B | 2.75B | 3.01B | 2.93B |
| Total Liabilities | 639M | 817M | 842M | 915M | 1.78B | 1.54B | 1.35B | 1.37B | 1.32B | 1.57B | 1.51B |
| Shareholders' Equity | 1.68B | 1.52B | 1.39B | 1.31B | 1.30B | 1.49B | 1.46B | 1.37B | 1.43B | 1.45B | 1.42B |
| Cash & Short-term Investments | 246M | 431M | 204M | 501M | 476M | 347M | 272M | 219M | 200M | 406M | 222M |
| Total Debt | 125M | 293M | 401M | 527M | 1.30B | 1.07B | 896M | 848M | 774M | 905M | 754M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 231M | 239M | 205M | 108M | 192M | 10.6M | 192M | 296M | 338M | 470M | 456M |
| Capital Expenditure | 42.5M | 46.6M | 57.6M | 39.6M | 39.9M | 31.1M | 26.0M | 48.9M | 50.3M | 77.7M | 150M |
| Free Cash Flow | 188M | 193M | 147M | 68.1M | 152M | -20.5M | 166M | 247M | 288M | 393M | 306M |
| Ratios | |||||||||||
| ROE | 7.3% | 2.2% | 9.3% | 15.4% | 5.9% | -10.9% | 6.7% | 10.0% | 16.2% | 17.4% | 19.0% |
| ROA | 5.3% | 1.4% | 5.7% | 9.1% | 2.5% | -5.4% | 3.4% | 5.0% | 8.5% | 8.4% | 9.2% |
| Net Profit Margin | 10.1% | 2.7% | 12.7% | 19.2% | 8.5% | -11.8% | 6.7% | 8.6% | 13.0% | 12.9% | 13.2% |
| Debt to Equity | 0.07x | 0.19x | 0.29x | 0.40x | 1.00x | 0.72x | 0.61x | 0.62x | 0.54x | 0.63x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Covista Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 30, 2016
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 3.23M | 0.07 | 3.3% |
| 2022 | USD 9.41M | 0.19 | - |
| 2021 | USD 1.72M | 0.03 | 2.2% |
| 2020 | USD 3.78M | 0.07 | 1.9% |
| 2019 | USD 17.4M | 0.29 | 13.5% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 22, 1998.
Who owns Covista Inc.
- Insiders 2.90%
- Institutions 97.10%
- Public & others 0.00%
- Shares outstanding 33.3M
- Free float 32.4M
Top funds holding CVSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.05M | 6.16% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.03M | 3.10% | +0.32% | Sep 2026 |
| iShares Russell 2000 ETF | 857K | 2.58% | 0.00% | Oct 2026 |
| Fidelity Low-Priced Stock | 792K | 2.38% | -0.06% | Aug 2026 |
| Vanguard Small Cap Index | 727K | 2.19% | -2.25% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 682K | 2.05% | +45.98% | Sep 2026 |
| American Funds SMALLCAP World A | 633K | 1.90% | -21.56% | Sep 2026 |
| Ariel Fund Investor | 594K | 1.79% | -15.42% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 474K | 1.42% | +0.28% | Sep 2026 |
| Putnam Small Cap Growth A | 399K | 1.20% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 398K | 1.20% | +15.21% | Aug 2026 |
| Fidelity Small Cap Index | 377K | 1.13% | +0.17% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 365K | 1.10% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 319K | 0.96% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 310K | 0.93% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 307K | 0.92% | -0.20% | Oct 2026 |
| DFA U.S. Targeted Value I | 293K | 0.88% | +7.32% | Sep 2026 |
| DFA US Micro Cap I | 265K | 0.80% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 260K | 0.78% | -2.93% | Sep 2026 |
| DFA U.S. Small Cap I | 259K | 0.78% | 0.00% | Sep 2026 |
Top institutions holding CVSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.48M | 16.48% | +4.80% | Jun 2026 |
| FMR Inc | 3.22M | 9.68% | +21.25% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.39M | 7.18% | -1.43% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.85M | 5.58% | +4.05% | Sep 2026 |
| Ariel Investments, LLC | 1.77M | 5.33% | -8.26% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.47M | 4.43% | -1.11% | Jun 2026 |
| State Street Corp | 1.39M | 4.18% | +2.97% | Jun 2026 |
| Capital World Investors | 1.06M | 3.20% | +3.33% | Jun 2026 |
| Geode Capital Management, LLC | 894K | 2.69% | +4.71% | Jun 2026 |
| Wellington Management Company LLP | 802K | 2.41% | -1.74% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 768K | 2.31% | +56.34% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 630K | 1.90% | -14.95% | Jun 2026 |
| LSV Asset Management | 600K | 1.81% | +21.30% | Jun 2026 |
| Franklin Templeton Inc | 567K | 1.71% | -2.05% | Jun 2026 |
| Boston Partners Global Investors, Inc | 567K | 1.71% | +18.65% | Jun 2026 |
| Alyeska Investment Group, L.P. | 552K | 1.66% | -18.85% | Jun 2026 |
| Fisher Asset Management, LLC | 506K | 1.52% | -10.63% | Jun 2026 |
| Charles Schwab Investment Management Inc | 483K | 1.45% | -3.39% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 473K | 1.42% | +12.83% | Jun 2026 |
| Northern Trust Corp | 435K | 1.31% | +4.99% | Jun 2026 |
Covista Inc. company profile
- Company name
- Covista Inc.
- Ticker
- CVSA.US
- Exchange
- USA Stocks
- Listed since
- Jun 21, 1991
- Sector
- Consumer Defensive
- Industry
- Diversified Consumer Services
- Employees
- 4,736
- Fiscal year end
- June
- Address
- 233 South Wacker Drive, Chicago, IL, United States, 60606
- Phone
- 312 651 1400
- Website
- covista.com
About Covista Inc.
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.
Covista Inc. management
10- Mr. Stephen W. Beard J.D.CEO & Chairman · born 1971
- Mr. Robert J. Phelan CPASenior VP & CFO · born 1965
- Mr. Douglas G. Beck J.D.Senior VP of Institutional Support Services, General Counsel & Corporate Secretary · born 1967
- Mr. Michael BetzChief Growth & Innovation Officer, Senior VP and President of Walden University · born 1973
- Mr. Scott Day LilesChief Strategy & Performance Officer and President of Medical and Veterinary · born 1966
- Mr. Manjunath GangadharanVP & Chief Accounting Officer · born 1983
- Mr. Jeremy CohenVice President of Investor Relations
- Ms. Sara HillSenior VP & Chief Human Resources Officer · born 1969
- Ms. Megan NoelSenior VP & Chief Corporate Affairs Officer · born 1985
- Ms. Amelia ManningPresident of Chamberlain University · born 1974